Perceptive Advisors LLC Kodiak Sciences Inc. Transaction History

Perceptive Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$7.09 - $89.45 $3.69 Million - $46.5 Million	-520,152 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$80.85 - $128.49 $4.76 Million - $7.57 Million	58,904 Added 12.77%	520,152 $44.1 Million
Q3 2021 Nov 15, 2021	BUY	$81.97 - $106.94 $14.4 Million - $18.7 Million	175,207 Added 61.25%	461,248 $44.3 Million
Q2 2021 Aug 16, 2021	SELL	$77.2 - $126.54 $7.95 Million - $13 Million	-102,967 Reduced 26.47%	286,041 $26.6 Million
Q1 2021 May 17, 2021	SELL	$110.45 - $164.47 $40 Million - $59.6 Million	-362,525 Reduced 48.24%	389,008 $44.1 Million
Q4 2020 Feb 16, 2021	SELL	$60.78 - $154.03 $17.7 Million - $44.9 Million	-291,488 Reduced 27.95%	751,533 $110 Million
Q3 2020 Nov 16, 2020	SELL	$45.05 - $59.27 $111 Million - $146 Million	-2,470,551 Reduced 70.31%	1,043,021 $61.8 Million
Q2 2020 Aug 14, 2020	SELL	$42.74 - $66.25 $6.41 Million - $9.94 Million	-149,985 Reduced 4.09%	3,513,572 $190 Million
Q4 2019 Feb 14, 2020	BUY	$13.9 - $76.65 $7.34 Million - $40.5 Million	528,358 Added 16.85%	3,663,557 $264 Million
Q4 2018 Feb 14, 2019	BUY	$6.11 - $10.43 $19.2 Million - $32.7 Million	3,135,199 New	3,135,199 $22.3 Million

39M

6.5K

5.8K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $485M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Perceptive Advisors LLC with notifications on news.